Get the Stockscreener App
6.11
9.35%
-0.63
Seres Therapeutics Inc stock is traded at $6.11, with a volume of 154.41K.
It is down -9.35% in the last 24 hours and down -5.86% over the past month.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
See More
Previous Close:
$6.74
Open:
$6.73
24h Volume:
154.41K
Relative Volume:
2.03
Market Cap:
$59.17M
Revenue:
$1.15M
Net Income/Loss:
$-46.90M
P/E Ratio:
-1.2176
EPS:
-5.0182
Net Cash Flow:
$-42.37M
1W Performance:
-21.06%
1M Performance:
-5.86%
6M Performance:
-60.96%
1Y Performance:
-50.53%
1-Day Range:
$6.025
$6.8477
1-Week Range:
$6.025
$8.25
52-Week Range:
$5.31
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
6.11 | 59.17M | 1.15M | -46.90M | -42.37M | -5.0182 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Form 4 Seres Therapeutics Inc For: 10 July By Investing.com - Investing.com South Africa
Seres Therapeutics (MCRB) awards 50,000 stock options to director-officer - Stock Titan
Seres Therapeutics (MCRB) awards 6,500-share stock option grant to director Dere - Stock Titan
Seres Therapeutics (MCRB) director receives 6,500 stock options at $7.14 strike - Stock Titan
Seres Therapeutics (MCRB) awards 7,500 stock options to company officer Marella Thorell - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Robert L. Rosiello - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Stephen Berenson - Stock Titan
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study - Yahoo Finance
Seres Therapeutics, Inc. Amends and Restates 2025 Incentive Award Plan in SEC 8-K Filing - Minichart
Seres Therapeutics (MCRB) H.C. Wainwright 4th Annual BioConnect Investor Conference summary - Quartr
Seres Therapeutics Shareholders Approve Directors and Executive Pay - TipRanks
Seres Therapeutics (NASDAQ: MCRB) investors back 900,000-share 2025 incentive plan increase - Stock Titan
Seres Therapeutics (MCRB) Q4 2025 earnings summary - Quartr
Why Is Seres Therapeutics Stock Falling Today?Seres Therapeutics (NASDAQ:MCRB) - Benzinga
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related AndropilatisSlideshow (NASDAQ:MCRB) 2026-07-08 - Seeking Alpha
Seres Therapeutics reports positive early SER-155 data - grafa.com
Seres’ SER-155 takes on immune checkpoint inhibitor-related enterocolitis - BioWorld News
MCRB: All proposals, including director elections and incentive plan amendment, were approved - TradingView
Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell - Moomoo
Seres Therapeutics reports positive SER-155 trial results - TipRanks
Seres Therapeutics (NASDAQ: MCRB) highlights promising SER-155 data and limited cash runway - Stock Titan
Seres Therapeutics unveils promising IST results for SER-155 in irEC patients - Traders Union
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment - The Manila Times
Seres Therapeutics outlines its microbiome drug strategy as MCRB works to regain traction - ad-hoc-news.de
Price to book forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView
MCRBSeres Therapeutics Inc Dividends - Finviz
MCRB News | SERES THERAPEUTICS INC (NASDAQ:MCRB) - ChartMill
Form 4 Seres Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Seres Therapeutics (NASDAQ: MCRB) director receives 7,508-share stock option grant - Stock Titan
Seres Therapeutics (NASDAQ: MCRB) director awarded 7,508 stock options at $7.94 - Stock Titan
Seres Therapeutics (MCRB) director awarded 7,508 stock options vesting by 2027 - Stock Titan
Clostridium Difficile Infections Market Forecast Signals Robust Industry Growth Through 2034 – DelveInsight | Seres Therapeutics, Nestlé Health Science, Adiso Therapeutics, Deinove, Acurx Pharma - Barchart.com
Price to sales forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView
Price to earnings forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView
Seres Therapeutics to Host Webcast on July 8, 2026, to - GlobeNewswire
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
This Insulet analyst begins coverage on a bullish note; here are top 5 initiations for Tuesday - MSN
H.C. Wainwright Initiates Seres Therapeutics(MCRB.US) With Buy Rating, Announces Target Price $12 - Moomoo
MCRB Initiates Coverage by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
H.C. Wainwright initiates Seres Therapeutics stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Seres Therapeutics stock coverage with buy rating By Investing.com - Investing.com Nigeria
HC Wainwright Initiates Seres Therapeutics at Buy With $12 Price Target - Moomoo
Seres Therapeutics Inc Cash Flow – DUS:1S90 - TradingView
EBITDA per share of Seres Therapeutics Inc – DUS:1S90 - TradingView
Return on assets % of Seres Therapeutics Inc – DUS:1S90 - TradingView
Total common shares outstanding of Seres Therapeutics Inc – DUS:1S90 - TradingView
Seres Therapeutics Inc (MCRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Seres Therapeutics Inc (MCRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Seres Therapeutics Inc (MCRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Seres Therapeutics Inc (MCRB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Seres Therapeutics Inc (MCRB) Institutional Confidence - TradingKey
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):